Literature DB >> 26712226

Lymphedema Precautions: Time to Abandon Old Practices?

Soojin Ahn1, Elisa R Port2.   

Abstract

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.A 46-year-old premenopausal woman with a body mass index of 21 was found on screening mammography to have a new, approximately 1-cm spiculated mass with associated calcifications in the upper outer quadrant of the left breast. Stereotactic core biopsy showed a focus of invasive duct carcinoma, strongly positive for estrogen and progesterone receptors and negative for human epidermal growth factor receptor 2, with associated ductal carcinoma in situ. Clinical examination revealed no palpable mass or axillary lymphadenopathy. She underwent a left lumpectomy with seed localization and sentinel lymph node biopsy. Final pathology revealed an 8-mm well-differentiated invasive carcinoma without lymphovascular invasion and intermediate grade ductal carcinoma in situ. The margins were clear, and three sentinel lymph nodes were negative for metastasis. The 21-gene recurrence score was 10, suggesting a 7% risk of 10-year distant recurrence with adjuvant endocrine treatment. After the completion of adjuvant radiotherapy (42.50 Gy in 16 fractions to the breast), the patient has returned for a follow-up visit. She is a professional violinist and would like to know what she can do to prevent lymphedema on her upcoming flight to Vienna.
© 2015 by American Society of Clinical Oncology.

Entities:  

Mesh:

Year:  2015        PMID: 26712226     DOI: 10.1200/JCO.2015.64.9574

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  5 in total

1.  Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Crystal S Denlinger; Tara Sanft; K Scott Baker; Gregory Broderick; Wendy Demark-Wahnefried; Debra L Friedman; Mindy Goldman; Melissa Hudson; Nazanin Khakpour; Allison King; Divya Koura; Robin M Lally; Terry S Langbaum; Allison L McDonough; Michelle Melisko; Jose G Montoya; Kathi Mooney; Javid J Moslehi; Tracey O'Connor; Linda Overholser; Electra D Paskett; Jeffrey Peppercorn; William Pirl; M Alma Rodriguez; Kathryn J Ruddy; Paula Silverman; Sophia Smith; Karen L Syrjala; Amye Tevaarwerk; Susan G Urba; Mark T Wakabayashi; Phyllis Zee; Nicole R McMillian; Deborah A Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2018-10       Impact factor: 11.908

Review 2.  Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments.

Authors:  Tessa C Gillespie; Hoda E Sayegh; Cheryl L Brunelle; Kayla M Daniell; Alphonse G Taghian
Journal:  Gland Surg       Date:  2018-08

3.  Diagnostic Methods, Risk Factors, Prevention, and Management of Breast Cancer-Related Lymphedema: Past, Present, and Future Directions.

Authors:  Hoda E Sayegh; Maria S Asdourian; Meyha N Swaroop; Cheryl L Brunelle; Melissa N Skolny; Laura Salama; Alphonse G Taghian
Journal:  Curr Breast Cancer Rep       Date:  2017-05-03

4.  Association Between Precautionary Behaviors and Breast Cancer-Related Lymphedema in Patients Undergoing Bilateral Surgery.

Authors:  Maria S Asdourian; Meyha N Swaroop; Hoda E Sayegh; Cheryl L Brunelle; Amir I Mina; Hui Zheng; Melissa N Skolny; Alphonse G Taghian
Journal:  J Clin Oncol       Date:  2017-10-04       Impact factor: 44.544

5.  The Reliability and Validity of Quality of Life Questionnaire Upper Limb Lymphedema (ULL-27) Turkish Patient With Breast Cancer Related Lymphedema.

Authors:  Ayşe Kayali Vatansever; Tuğba Yavuzşen; Didem Karadibak
Journal:  Front Oncol       Date:  2020-05-12       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.